Articles on metformin & combinations from NPS RADARArticles on metformin & combinations from NPS RADAR

Title Content Type Date Description
Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet): streamlined authority removed Professional publication - NPS RADAR - Brief item 2011-07-01 00:00:00 Due to continuing safety concerns, rosiglitazone can no longer be prescribed under a streamlined authority.
Sitagliptin, vildagliptin and saxagliptin — dipeptidyl peptidase-4 inhibitors (‘gliptins’) for add-on therapy in type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2011-07-01 00:00:00 DPP-4 inhibitors (‘gliptins’) are a recently introduced class of oral drugs for improving glycaemic control in patients with type 2 diabetes mellitus. They are approved as add-on therapy in combination with either metformin or a sulfonylurea in patients poorly controlled with metformin, a sulfonylurea or a thiazolidinedione. The RADAR article on gliptins has been updated to reflect the listing of another gliptin. Saxagliptin was added to the PBS on 1 June 2011.
Sitagliptin with metformin (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus Professional publication - NPS RADAR - Brief item 2009-08-01 00:00:00 Sitagliptin with metformin tablets (Janumet) in fixed-dose combinations of 50/500 mg, 50/850 mg and 50/1000 mg are available on the PBS as of 1 August 2009.
Intolerance and contraindications to metformin Professional publication - NPS RADAR - Web only item 2008-12-01 00:00:00 Lists adverse effects of and contraindications to metformin, including gastrointestinal symptoms, lactic acidodis, and renal impairment.
Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2008-12-01 00:00:00 Rosiglitazone improves glycaemic control but there is a lack of evidence that it improves diabetes–related clinical complications and mortality. Rosiglitazone is no longer indicated in combination with insulin or for triple oral therapy in combination with metformin and a sulfonylurea. Rosiglitazone is a third-line choice. It may still be considered as part of dual therapy when either metformin or a sulfonylurea is contraindicated or not tolerated. Insulin should also be considered instead of rosiglitazone in these scenarios. Do not use rosiglitazone in people with heart failure or a history of heart failure.
Rosiglitazone with metformin combination tablets (Avandamet) listed on the PBS. Professional publication - NPS RADAR - Brief item 2006-12-01 00:00:00 Rosiglitazone with metformin in a fixed-dose combination tablet (Avandamet) was listed on the PBS as a third-line choice, after metformin and/or a sulfonylurea.
Metformin/glibenclamide (Glucovance) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2005-12-01 00:00:00 Reviews use of metformin/glibenclamide combination tablets for type 2 diabetes mellitus, including comparison with co-administered drugs and risk of hypoglycaemia.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-30 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.